Gary Gordon, MD, PhD is a senior biopharmaceutical executive with vast experience in the development of drugs from first in-human studies to approval and commercialization. Most recently, Gary served as Vice President of Oncology Development at AbbVie Inc., where he advanced the organization’s oncology pipeline through the FDA approval of venetoclax, obtained four Break Through Designations and several Orphan Drug Designations. Prior to AbbVie, Gary held a position at Abbott Laboratories as Divisional Vice President of Global Oncology Development, where he advanced numerous compounds from Phase 0 through Phase 3 and developed partnerships to support programs, as well as at Ovation Pharmaceuticals Inc. as Chief Scientific Officer and Vice President of Clinical Affairs. Gary earned his B.S. at State University of New York at Stony Brook and his PhD and MD from The Johns Hopkins University School of Medicine where he was also an Assistant Professor of Oncology.